<?xml version="1.0" encoding="UTF-8" ?>
			<?xml-stylesheet href="/rss/rss2html.xsl" type="text/xsl" media="screen"?>
			<rss version="2.0" xmlns:alacra="http://www.alacra.com" xmlns:bir="http://www.alacra.com/bir" xmlns:ccbn="http://www.alacra.com/ccbn" xmlns:srp="http://www.alacra.com/srp" xmlns:newstex="http://www.alacra.com/newstex" ><channel><title>Peregrine Pharmaceuticals Inc RSS Research Feed - Subscribe Today - AlacraStore.com</title>
<description>Peregrine Pharmaceuticals Inc</description>
<link>http://www.alacrastore.com/company-snapshot/Peregrine_Pharmaceuticals_Inc-2110987</link>
<lastBuildDate>Saturday, October 11, 2008 3:33:28 AM</lastBuildDate>
<alacra:xlsid>2110987</alacra:xlsid>
<alacra:company>Peregrine Pharmaceuticals Inc</alacra:company>
<language>en</language>
<generator>AlacraStore RSS Builder 1.0</generator>
<ttl>30</ttl>
<item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-28112761</link><guid isPermaLink="false">newstex/PRN-0005-28112761</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> TUSTIN, Calif., Sep. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016019</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016047</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>9/17/2008 8:18:47 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18013000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>Nasdaq Panel Grants Peregrine Pharmaceuticals' Request for 180-Day Extension for Continued Listing on Nasdaq</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-28112761</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">NASDAQ STOCK MARKET INC</newstex:index_entry_company><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PEREGRINE PHARMACEUTICALS INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">NDAQ</newstex:index_entry_ticker><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PPHM</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-27854680</link><guid isPermaLink="false">newstex/PRN-0005-27854680</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> TUSTIN, Calif., Sep. #, #### (PRNewswire-FirstCall delivered by Newstex) -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the first quarter of fiscal year #### on September...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016048</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016018</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>9/3/2008 8:17:25 AM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18008000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18004000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-27854680</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PEREGRINE PHARMACEUTICALS INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PPHM</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/bir/324638</link><guid isPermaLink="false">bir/324638</guid><bir:index_mode xmlns:bir="http://www.alacra.com/bir">norm</bir:index_mode><title>Peregrine Pharmaceuticals Inc.</title><bir:company xmlns:bir="http://www.alacra.com/bir">Peregrine Pharmaceuticals Inc.</bir:company><bir:company xmlns:bir="http://www.alacra.com/bir">Techniclone International Corp.</bir:company><bir:company xmlns:bir="http://www.alacra.com/bir">Cancer Biologics Inc.</bir:company><bir:company xmlns:bir="http://www.alacra.com/bir">Peregrine Pharmaceuticals, Inc.</bir:company><bir:company xmlns:bir="http://www.alacra.com/bir">Techniclone Corp.</bir:company><bir:cou xmlns:bir="http://www.alacra.com/bir">United States</bir:cou><bir:descr xmlns:bir="http://www.alacra.com/bir">Manufacturing: Research, development and commercialization of novel cancer therapeutics.</bir:descr><bir:sic xmlns:bir="http://www.alacra.com/bir">2835</bir:sic><bir:naics xmlns:bir="http://www.alacra.com/bir">325413</bir:naics><bir:class xmlns:bir="http://www.alacra.com/bir">17</bir:class><bir:size xmlns:bir="http://www.alacra.com/bir">C</bir:size><bir:revenue xmlns:bir="http://www.alacra.com/bir">D</bir:revenue><bir:ticker xmlns:bir="http://www.alacra.com/bir">PPHM</bir:ticker><pubDate>8/26/2008 6:21:43 AM</pubDate><bir:docid xmlns:bir="http://www.alacra.com/bir">324638</bir:docid><category>Company Profiles &amp; Financials</category><alacra:ip>Gale Company Profiles</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/newstex/PRN-0005-26875457</link><guid isPermaLink="false">newstex/PRN-0005-26875457</guid><newstex:index_mode xmlns:newstex="http://www.alacra.com/newstex">xml</newstex:index_mode><description> TUSTIN, Calif., Jul. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced that it received a Staff Determination letter from the Nasdaq Stock Market (NASDAQ) on July...</description><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07005000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04002006</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">04016019</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07014012</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">07003001</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13000000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010000</newstex:cat><newstex:cat xmlns:newstex="http://www.alacra.com/newstex">13010005</newstex:cat><pubDate>7/23/2008 5:16:54 PM</pubDate><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18000000</newstex:event><newstex:event xmlns:newstex="http://www.alacra.com/newstex">18013000</newstex:event><newstex:Publication xmlns:newstex="http://www.alacra.com/newstex">PR Newswire US</newstex:Publication><title>Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule</title><newstex:docid xmlns:newstex="http://www.alacra.com/newstex">PRN-0005-26875457</newstex:docid><newstex:index_entry_company xmlns:newstex="http://www.alacra.com/newstex">PEREGRINE PHARMACEUTICALS INC</newstex:index_entry_company><newstex:index_entry_ticker xmlns:newstex="http://www.alacra.com/newstex">PPHM</newstex:index_entry_ticker><category>News</category><alacra:ip>Newstex</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T1897032</link><guid isPermaLink="false">ccbn/T1897032</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Hello this is the (inaudible) operator. Welcome to the Peregrine Pharmaceuticals fourth-quarter #### financial results conference call. All participants will be in a listen-only mode. There will be an opportunity for you to ask questions at the end of today's presentation. (OPERATOR INSTRUCTIONS) For your information, this conference is being recorded. I would like to turn the call over now Miss Barbara Lindheim. Miss Lindheim? ...

</description><pubDate>7/14/2008 2:03:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Peregrine Pharmaceuticals</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Q4 2008 Peregrine Pharmaceuticals Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">PPHM</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:30am ET</ccbn:time><title>Q4 2008 Peregrine Pharmaceuticals Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1897032</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T1787533</link><guid isPermaLink="false">ccbn/T1787533</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Hello and welcome to the Peregrine Pharmaceuticals third-quarter #### financial results conference call. All participants will be in a listen-only mode and there will be an opportunity for you to ask questions at the end of today's presentation. (OPERATOR INSTRUCTIONS). For your information this conference is being recorded. At this time I would like to turn the conference over to Barbara Lindheim. Ms. Lindheim, you may begin the conference. ...

</description><pubDate>3/11/2008 4:05:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Peregrine Pharmaceuticals</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Q3 2008 Peregrine Pharmaceuticals Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">PPHM</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:30am ET</ccbn:time><title>Q3 2008 Peregrine Pharmaceuticals Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1787533</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T1752434</link><guid isPermaLink="false">ccbn/T1752434</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>Peregrine Pharmaceuticals at BIO CEO &amp; Investor Conference</description><pubDate>2/12/2008 3:06:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Peregrine Pharmaceuticals</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Peregrine Pharmaceuticals at BIO CEO &amp; Investor Conference Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">PPHM</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">9:30am ET</ccbn:time><title>Peregrine Pharmaceuticals at BIO CEO &amp; Investor Conference Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1752434</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson StreetEvents</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/srp/26785</link><guid isPermaLink="false">srp/26785</guid><srp:index_mode xmlns:srp="http://www.alacra.com/srp">norm</srp:index_mode><description>...Address:##### Franklin Avenue, Suite ###, Tustin, California #####-#### Incorporated:DelawareWeb Site: www.peregrineinc.comSIC Classification: In Vitro and In Vivo Diagnostic Substances (####) Business Description: Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the research and development and commercialization of cancer therapeutics and cancer diagnostics through a series of proprietary platform technologies using monoclonal antibodies. ...

</description><srp:company xmlns:srp="http://www.alacra.com/srp">26785</srp:company><title>Peregrine Pharmaceuticals, Inc.</title><srp:cusip xmlns:srp="http://www.alacra.com/srp">713661106</srp:cusip><srp:ticker xmlns:srp="http://www.alacra.com/srp">PPHM</srp:ticker><pubDate>10/6/2006 12:16:00 PM</pubDate><srp:docid xmlns:srp="http://www.alacra.com/srp">26785</srp:docid><category>Credit &amp; Investment Research</category><alacra:ip>SharkRepellent.net</alacra:ip></item></channel></rss>